A Real Estate Firm Has Made An AI Infrastructure Play – And Its Stock Is Surging

• If completed, current La Rosa shareholders would own about 3.1% of the combined company.
• Consensus develops high-performance data centers and GPU cloud platforms across the U.S. and Canada.
• Consensus will appoint the post-transaction CEO and chairman.

Shares of La Rosa Holdings Corp (LRHC) surged more than 25% on Monday after the company made its foray into the AI infrastructure market with the acquisition of a minority stake in Consensus Core Technologies.

La Rosa signed a non-binding letter of intent to acquire Consensus, a provider of infrastructure for artificial intelligence and high-performance computing, in an all-stock deal, with no cash consideration.

If completed, current La Rosa shareholders would own about 3.1% of the combined company, while Consensus equity holders would control the remaining 96.9%. Consensus will also appoint the post-transaction CEO and chairman.

Consensus develops high-performance data centers and GPU cloud platforms across the U.S. and Canada.

"The global demand for AI computing infrastructure is expanding at an extraordinary pace, and we believe Consensus is well positioned to play an important role in meeting that demand. Combined with significant power capacity and its partnership with NVIDIA, in our view, Consensus is well positioned to build the scalable infrastructure needed to support the next wave of AI workloads," said Joe La Rosa, CEO of La Rosa Holdings Corp.

"This opportunity aligns with our strategy of identifying high-growth platforms where we can combine operational expertise with access to the public markets to accelerate expansion and create long-term shareholder value."

How Did Stocktwits Users React?

Retail sentiment on Stocktwits for LRHC flipped to "bullish" from "bearish" a day earlier, amid "high" message volumes.

One user said that the setup can surprise.

One user expects a breakout beyond $1.25.

Read also: QURE Jumps 20% – Analysts Upgrade Stock On Huntington’s Disease Therapy Update, Retail Eyes $150

For updates and corrections, email newsroom[at]stocktwits[dot]com.